Thierry Bernard

Thierry Bernard is the Chief Executive Officer and Managing Director of QIAGEN N.V., a position he has held since March 2020. As a visionary leader in the molecular diagnostics and life sciences industry, Bernard has spearheaded QIAGEN's transformation into a digital-first organization, achieving remarkable milestones including 72% of business transactions processed through digital platforms representing $700M in revenues and serving over 150,000 customers through personalized digital features. Under his strategic leadership, QIAGEN has consistently exceeded financial outlooks and delivered strong growth across its Sample to Insight solutions portfolio. Bernard's approach emphasizes 'relentless transformation' - continuous evolution that challenges traditional approaches to leadership and innovation in the healthcare sector. His commitment to global health access is exemplified by his belief that 'healthcare is, first and foremost, a right' and his advocacy for quality diagnostics access worldwide. Beyond QIAGEN, Bernard serves as Chair of the AdvaMedDx Board of Directors since March 2023, a U.S. industry trade association representing in vitro diagnostic manufacturers, and joined the Board of Directors of Neogen Corporation in 2024. His multi-lingual capabilities and extensive international experience spanning over two decades in leadership roles across Europe, Asia, and the Americas have positioned him as a respected voice in the global life sciences community. Bernard's educational foundation from prestigious institutions including Sciences Po, Harvard Business School, and the London School of Economics, combined with his appointment as Conseiller du Commerce Extérieur by the French government, underscores his expertise in international business development and strategic leadership.